Advertisement

External Validation of the OAC3-PAD Risk Score to Predict Major Bleeding Events Using the Prospective GermanVasc Cohort Study

Published:August 08, 2022DOI:https://doi.org/10.1016/j.ejvs.2022.07.055
      Finding the optimal antithrombotic treatment for patients with lower limb peripheral arterial disease (PAD) can be challenging for clinicians, since high level evidence remains sparse more than 30 years after David L. Sackett, the godfather of evidence based medicine, called for better “rules of evidence and clinical recommendations on the use of antithrombotic agents”.
      • Sackett D.L.
      Rules of evidence and clinical recommendations on the use of antithrombotic agents.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Vascular and Endovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sackett D.L.
        Rules of evidence and clinical recommendations on the use of antithrombotic agents.
        Chest. 1989; 95 (2S–4S)
        • Ducrocq G.
        • Wallace J.S.
        • Baron G.
        • Ravaud P.
        • Alberts M.J.
        • Wilson P.W.
        • et al.
        Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.
        Eur Heart J. 2010; 31: 1257-1265
        • Behrendt C.A.
        • Kreutzburg T.
        • Nordanstig J.
        • Twine C.P.
        • Marschall U.
        • Kakkos S.
        • et al.
        The OAC3-PAD risk score predicts major bleeding events one year after hospitalisation for peripheral artery disease.
        Eur J Vasc Endovasc Surg. 2022; 63: 503-510
        • Kotov A.
        • Peters F.
        • Debus E.S.
        • Zeller T.
        • Heider P.
        • Stavroulakis K.
        • et al.
        The prospective GermanVasc cohort study.
        VASA. 2022; 50: 446-452
        • Sweeting M.J.
        • Ulug P.
        • Roy J.
        • Hultgren R.
        • Indrakusuma R.
        • Balm R.
        • et al.
        Ruptured Aneurysm Collaborators: AJAX trial investigators; ECAR trial investigators; IMPROVE trial investigators: management committee; STAR cohort investigators. Value of risk scores in the decision to palliate patients with ruptured abdominal aortic aneurysm.
        Br J Surg. 2018; 105: 1135-1144
        • Kreutzburg T.
        • Peters F.
        • Kuchenbecker J.
        • Marschall U.
        • Lee R.
        • Kriston L.
        • et al.
        Editor's Choice – The GermanVasc score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease.
        Eur J Vasc Endovasc. 2021; 61: 248-256